QuickView for YDL103C;jsessionid=15F15BB478DC6C77651BC16CE76A6F8A;jsessionid=FA09DD4A5D65571BA1AD979499E356E2;jsessionid=5DB5107377C50D220B2B02849FAC3A0E;jsessionid=2766B9A4379564671E9BCB65AB596CAF;jsessionid=A06FF884E94C89B37D11661C0B1FCC3D;jsessionid=669E05DFB88433FFB84D7B1D47F570BD;jsessionid=520E870494C5E30DC2AF39C70AC1E9C5;jsessionid=4CFE25E4472077B14406FC2150D78D47;jsessionid=6659347155A5C3AD2FAAE3DFA03DF9CD;jsessionid=9E266D66B12AA9A9A2DE843D211879D2;jsessionid=394B6BE88C8D707E4FD1CCECA787FE8F;jsessionid=F9135D10EFC71BBB9470E9675D6AD617 (gene)

1. Cyst fluid glycoproteins accurately distinguishing malignancies of pancreatic cystic neoplasm.
2. Clinical Evaluation of Cystic Renal Masses With Bosniak Classification by Contrast-Enhanced Ultrasou…
3. Feasibility of Surveillance for Mucinous Cystic Neoplasm of the Pancreas: A Multi-Institutional Retr…
4. Clinicopathological and genetic characteristics of congenital cystic adenomatoid malformation of lun…
5. The added value of contrast-enhanced ultrasound in evaluation of indeterminate small solid renal mas…

There were no clinical trials for YDL103C;jsessionid=15F15BB478DC6C77651BC16CE76A6F8A;jsessionid=FA09DD4A5D65571BA1AD979499E356E2;jsessionid=5DB5107377C50D220B2B02849FAC3A0E;jsessionid=2766B9A4379564671E9BCB65AB596CAF;jsessionid=A06FF884E94C89B37D11661C0B1FCC3D;jsessionid=669E05DFB88433FFB84D7B1D47F570BD;jsessionid=520E870494C5E30DC2AF39C70AC1E9C5;jsessionid=4CFE25E4472077B14406FC2150D78D47;jsessionid=6659347155A5C3AD2FAAE3DFA03DF9CD;jsessionid=9E266D66B12AA9A9A2DE843D211879D2;jsessionid=394B6BE88C8D707E4FD1CCECA787FE8F;jsessionid=F9135D10EFC71BBB9470E9675D6AD617